Polypill strategy for primary prevention of cardiovascular disorders

Drugs of Today

Volumn 49, Issue 5, 2013, Pages 317-324

  Dabhadkar, K C ^a   Bellam, N ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular diseases; Cardiovascular drugs; Fixed dose combination; Polypill

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; HYDROCHLOROTHIAZIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLYCAP; RAMIPRIL; SIMVASTATIN; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; COUGHING; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DYSPEPSIA; FOLLOW UP; HUMAN; HYPERKALEMIA; MORTALITY; MUSCULOSKELETAL PAIN; PILL; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; SYSTOLIC BLOOD PRESSURE; TREATMENT WITHDRAWAL;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR DRUGS; FIXED-DOSE COMBINATION; POLYPILL;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; HUMANS; PATENTS AS TOPIC; PRIMARY PREVENTION; RISK FACTORS;

EID: 84878727038     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.5.1950148     Document Type: Review

References (18)

1. Murray, C.J., Vos, T., Lozano, R. et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380(9859): 2197-223.
2. Lozano, R., Naghavi, M., Foreman, K. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380(9859): 2095-128.
3. Yusuf, S., Hawken, S., Ounpuu, S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364(9438): 937-52. (Pubitemid 39208455)
4. Canto, J.G., Kiefe, C.I., Rogers, W.J. et al. Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. JAMA 2011, 306(19): 2120-7.
5. Dabhadkar, K.C., Kulshreshtha, A., Ali, M.K., Narayan, K.M. Prospects for a cardiovascular disease prevention polypill. Annu Rev Public Health 2011, 32: 23-38.
6. Wald, N.J., Law, M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003, 326(7404): 1419.
7. Patel, A., Shah, T., Shah, G. et al. Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel fiveingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers. Am J Cardiovasc Drugs 2010, 10(2): 95-103.
8. Yusuf, S., Pais, P., Afzal, R. et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009, 373(9672): 1341-51.
9. Wald, D.S., Morris, J.K., Wald, N.J. Randomized Polypill crossover trial in people aged 50 and over. PLoS One 2012, 7(7): e41297.
10. Soliman, E.Z., Mendis, S., Dissanayake, W.P., Soma-sundaram, N.P., Gunaratne, P.S., Jayasingne, I.K., Furberg, C.D. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials 2011, 12: 3.
11. Thom, S.A. Field, J., Poulter, N.R. et al. Use of a multidrug pill in reducing cardiovascular events (UMPIRE). Circulation 2012, 126(23): 2781.
12. Gaziano, T.A., Opie, L.H., Weinstein, M.C. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 2006, 368(9536): 679-86.
13. van Gils, P.F., Over, E.A., Hamberg-van Reenen, H.H., de Wit, G.A., van den Berg, M., Schuit, A.J., Engelfriet, P.M. The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. BMJ Open 2011, 1(2): e000363.
14. Bautista, L.E., Vera-Cala, L.M., Ferrante, D. et al. A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America. Health Aff (Millwood) 2013, 32(1): 155-64.
15. Wald, D.S., Wald, N.J. Implementation of a simple agebased strategy in the prevention of cardiovascular disease: the Polypill approach. J Eval Clin Pract 2012, 18(3): 612-5.
16. Malekzadeh, F., Marshall, T., Pourshams, A. et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. Int J Clin Pract 2010, 64(9): 1220-7.
17. Rodgers, A., Patel, A., Berwanger, O. et al. An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. PLoS One 2011, 6(5): e19857.
18. Yusuf, S., Pais, P., Sigamani, A., Xavier, D., Afzal, R., Gao, P., Teo, K.K. Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators. Circ Cardiovasc Qual Outcomes 2012, 5(4): 463-71.